Systematic review and meta-analysis
Why this level?
Specify the research question: intervention, diagnostic accuracy, prognosis, aetiology, or screening intervention. Other question types are outside this hierarchy. NHMRC 2009 sourceA review of at least two Level II studies can be Level I within the relevant question category. Reviews of lower-level studies retain those levels; mixed designs require assessment of the studies contributing to each outcome. Review quality is appraised separately.
Where the NHMRC 2009 hierarchy names this design, it places it here:
| Research question | Level | When |
|---|---|---|
| Intervention | I | Review of at least two Level II studies for the specified outcome. NHMRC assigns Level I to this combination. |
| Intervention | III-2 | Review of at least two Level III-2 studies for the specified outcome. A review of lower-level studies retains their level. |
What question does this help answer?
What the whole body of evidence says, rather than what one study said. It is also the honest way to find out that the evidence does not answer the question, which a narrative summary tends to hide.
Systematic review and meta-analysis are separable
The review is the search, the selection and the appraisal. The meta-analysis is the statistical combination, and it is optional. Studies that are too different in population, intervention or outcome should be reviewed and described without being pooled; a pooled number that averages incomparable things is worse than no number.
The PRISMA 2020 flow
The protocol comes first
Registering the protocol, in PROSPERO or equivalent, before the search is what separates a systematic review from a literature summary assembled around a conclusion. Eligibility criteria, outcomes, the synthesis method and the subgroup questions are all decided in advance, because every one of them can be steered by knowing what the studies found.
Key assumptions and design requirements
- The search covers more than one database and is reproducible, with the full strategy reported.
- Screening and data extraction are done by two people independently, with disagreement resolved by a stated process.
- Risk of bias is assessed per study with a named tool, and it feeds the interpretation rather than sitting in an appendix.
- The synthesis method, fixed-effect or random-effects, is chosen for a reason and stated with it.
- Small-study effects and publication bias are examined when the number of studies makes it meaningful.
Heterogeneity is a finding, not an obstacle
Studies differ because the world differs, so some heterogeneity is expected. The test for heterogeneity has low power with few studies, so a non-significant result is not evidence of consistency, and I-squared describes what PROPORTION of variability is not chance rather than how much variability there is. Large heterogeneity is a reason to ask why the studies disagree, which is often the most useful part of the review.
Why Mallard may recommend it
Mallard may point here when a description asks what is already known, or proposes to pool published results rather than collect new data.
How it is sized
There is no sample size calculation for a systematic review in the usual sense: the number of studies is whatever the literature contains. Mallard does not produce a headline N for this design. Where a review is planned prospectively, the relevant question is what precision the available evidence could support, which is closer to a feasibility assessment than a power calculation.
What to watch out for
Combining studies does not remove their biases, it averages them, and a meta-analysis of flawed studies produces a precise flawed answer. Heterogeneity is not a nuisance to be tested away: a small p-value for heterogeneity is not required before taking real differences between studies seriously, and a large I-squared does not by itself forbid pooling.
Clinical example
Question: Does early mobilisation after cardiac surgery reduce length of stay? Design: Register a protocol, search at least two databases with a documented strategy, screen in duplicate, appraise each trial for risk of bias, and pool only within groups of trials whose populations and mobilisation protocols are close enough that a single average means something.
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (opens in a new tab) · BMJ · doi 10.1136/bmj.n71
- Measuring inconsistency in meta-analyses (opens in a new tab) · BMJ · doi 10.1136/bmj.327.7414.557